Did the company announce any partnership, licensing or collaboration deals that could affect future revenue streams?

Answer to the question

No – the press release does not mention any new partnership, licensing, or collaboration agreements. The corporate update is limited to the Q2‑2025 earnings results and a status‑check on LAVA’s proprietary Gammabody® bispecific γδ‑T‑cell engagers, with no disclosed external deals that would materially augment future revenue streams.

Trading implications

• Fundamentals: With no partnership or out‑licensing revenue to offset the high R&D spend, LAVA’s near‑term cash‑flow outlook remains tied to its own clinical milestones. The lack of a non‑dilutive revenue source means the company is still heavily dependent on successful trial read‑outs (e.g., the upcoming Phase 2 data for its lead Gammabody candidates) to justify the current valuation. Until a partnership materializes, the risk‑/reward profile stays skewed toward a “high‑risk, high‑potential” play.

• Technical view: The stock has been trading in a relatively tight range around the $1.20–$1.35 band since the Q2 release, with the 20‑day SMA hovering near the upper end of that range. Volume has been light, indicating limited conviction from either side. In the absence of a partnership catalyst, a breakout to the upside would likely need to be driven by a positive clinical update; a downside break toward the 20‑day SMA (~$1.20) could be triggered by any delay or negative data.

• Actionable stance:

  • Long‑biased if you are comfortable with a speculative play on the upcoming Gammabody trial read‑outs—target the $1.35 resistance with a stop around $1.20.
    
  • Short‑biased if you view the lack of partnership‑driven cash‑flow as a red flag and the stock is over‑priced on future potential—target the $1.20 support level with a stop near $1.35.
    

Overall, without a disclosed partnership or licensing deal, the stock’s upside remains contingent on internal clinical progress, and the market will price in that risk until a concrete collaboration is announced.